
AU  - Mossad, Emad B.
AU  - Baijal, Rahul
AU  - Krishnamurthy, Raj
C7  - pp. 314-335
TI  - Preoperative Evaluation and Preparation
SN  - 9781118768259
UR  - https://doi.org/10.1002/9781118768341.ch14
DO  - doi:10.1002/9781118768341.ch14
SP  - 314-335
KW  - incidence
KW  - classification
KW  - consenting
KW  - laboratory testing
KW  - cardiac imaging
KW  - fasting
KW  - premedication
KW  - infective endocarditis
KW  - risk stratification
PY  - 2015
AB  - Summary The preoperative period is a critical step in the care of children and adults with congenital heart disease. This chapter reviews the essential goals of the preoperative visit in preparing the child and family for the upcoming intervention, obtaining appropriate consent, and understanding the child's cardiac condition and other medical issues. This chapter will discuss the role of history and physical examination, various investigations including laboratory tests and imaging studies, and evaluation of compensatory status. We discuss the options for premedication, fasting guidelines, and infective endocarditis prophylaxis. We also describe a method for anesthetic risk stratification in children with congenital heart disease presenting for cardiac as well as non-cardiac interventions.
ER  - 

TY  - JOUR
TI  - Respiratory Nurses SIG: Oral Session 1
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9781118768259
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_1.x
DO  - doi:10.1111/j.1440-1843.2011.01936_1.x
SP  - 9
EP  - 9
PY  - 2011
ER  - 

TY  - JOUR
TI  - Primary Care SIG: Oral Session
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9781118768259
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_12.x
DO  - doi:10.1111/j.1440-1843.2011.01936_12.x
SP  - 23
EP  - 24
PY  - 2011
ER  - 

TY  - JOUR
TI  - Cochrane Group Oral Session
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9781118768259
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_4.x
DO  - doi:10.1111/j.1440-1843.2011.01936_4.x
SP  - 11
EP  - 12
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - Basic Clin Pharmacol Toxicol
VL  - 125
IS  - S2
SN  - 9781118768259
UR  - https://doi.org/10.1111/bcpt.13297
DO  - doi:10.1111/bcpt.13297
SP  - 3
EP  - 330
PY  - 2019
ER  - 

TY  - JOUR
TI  - Respiratory Infectious Diseases SIG: Oral Session
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9781118768259
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_22.x
DO  - doi:10.1111/j.1440-1843.2011.01936_22.x
SP  - 35
EP  - 36
PY  - 2011
ER  - 

TY  - JOUR
TI  - Cell Biology/Immunology SIG: Oral Session 1
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9781118768259
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_3.x
DO  - doi:10.1111/j.1440-1843.2011.01936_3.x
SP  - 10
EP  - 11
PY  - 2011
ER  - 

C7  - pp. 43-62
TI  - Respiratory Therapeutics
SN  - 9781119482284
UR  - https://doi.org/10.1002/9781119482307.ch3
DO  - doi:10.1002/9781119482307.ch3
SP  - 43-62
KW  - antibiotic therapy
KW  - lower respiratory tract disease
KW  - metered-dose inhalers
KW  - nebulization
KW  - upper respiratory tract disease
PY  - 2011
AB  - Summary Antibiotics are often required for the management of acute and chronic respiratory diseases and are essential to reduce morbidity as well as mortality. Acute infectious upper respiratory tract disease in the cat is most commonly ascribed to viral infection, and when secondary bacterial invasion is suspected, empiric antibiotic therapy is often used. Lower respiratory tract infection can be life threatening and antibiotics should be based on culture and susceptibility testing whenever possible. Fungal infection in the respiratory tract most commonly involves Cryptococcus neoformans or Aspergillus fumigatus in the nasal cavity of cats or dogs, respectively, and Histoplasma capsulatum, Blastomyces dermatitidis, or Coccidioides immitis organisms in the lower respiratory tract. Nebulization can be used to hydrate airway secretions or to administer drug directly to the epithelial surface of the respiratory tract. Various corticosteroid preparations are available as metered-dose inhalers.
ER  - 

TY  - JOUR
AU  - SONI, NEIL
AU  - THOMAS, BENJAMIN
TI  - The benefits of allogeneic erythrocyte transfusion: what evidence do we have?
JO  - Transfusion Alternatives in Transfusion Medicine
VL  - 10
IS  - 3
SN  - 9781119482284
UR  - https://doi.org/10.1111/j.1778-428X.2008.00111.x
DO  - doi:10.1111/j.1778-428X.2008.00111.x
SP  - 147
EP  - 159
KW  - Clinical use
KW  - Efficacy
KW  - Indications
KW  - Red blood cell transfusion
KW  - Safety
KW  - Transfusion triggers
PY  - 2008
AB  - SUMMARY Restrictive blood transfusion practice has modified the indications for blood transfusion. There is still a need for succinct definition of transfusion thresholds in different situations, based on physiological argument balancing the mechanisms by which blood is potentially beneficial against the deleterious effects of transfusion, whether known, speculative or unknown. The latter still need identification. The key physiological benefit is through oxygen delivery and thereby the provision of a margin of safety in tissue oxygenation. This can be achieved by a range of methods that safeguard blood volume, conserve blood or increase hemoglobin as well as by transfusion, and in many situations conservation methods can or could now preclude transfusion. There are still acute and less controlled or controllable situations where conservation methods are difficult to implement or may need to be complemented by transfusion. These are the indications that still need clarification. Difficult and confusing areas of practice include the management of patients with ischemic heart disease. This is a potential driver for transfusion to prevent ischemia, but clarity of efficacy or detriment is elusive beyond acknowledging that both too high and too low hemoglobin values are detrimental. The issue in all clinical situations, whether acute or chronic, is to continue to reevaluate the safety of current thresholds. This will help limit blood usage and ensure that blood is used when necessary but not otherwise.
ER  - 

TY  - JOUR
TI  - Oliv SIG: Oral Session 2
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9781119482284
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_10.x
DO  - doi:10.1111/j.1440-1843.2011.01936_10.x
SP  - 19
EP  - 21
PY  - 2011
ER  - 

TY  - JOUR
TI  - Cystic Fibrosis SIG: Oral Session
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9781119482284
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_16.x
DO  - doi:10.1111/j.1440-1843.2011.01936_16.x
SP  - 27
EP  - 28
PY  - 2011
ER  - 

AU  - Glover, Mark
C7  - pp. 357-375
TI  - Work in Hyperbaric Environments
SN  - 9780470515945
UR  - https://doi.org/10.1002/9780470710425.ch25
DO  - doi:10.1002/9780470710425.ch25
SP  - 357-375
KW  - work in hyperbaric environments
KW  - direct and indirect relevance to respiratory tract - when exposed to environmental pressures
KW  - working breath-hold divers - well-developed competitive sport, based on breath-hold diving
KW  - self-contained underwater breathing apparatus (SCUBA) - divers exhaling air released, using principle of ‘open circuit’
KW  - deep, long dives commercial divers - remaining at pressure for weeks at a time
KW  - hyperbaric exposures – tunnel, SCUBA, surface supply, bell and saturation
KW  - surface-oriented working divers - returning to normobaric conditions after each dive
KW  - atelectasis, breathing high fraction of oxygen - in normobaric and hyperbaric conditions
KW  - pressure-related change in volume in gas-filled spaces - inflicting barotrauma
KW  - hypercapnia, complication - and limiting factor in hyperbaric environments
PY  - 2011
AB  - Summary This chapter contains sections titled: Introduction Respiratory hazards, diseases and their management Further information Further reading
ER  - 

TY  - JOUR
TI  - Tobacco & Related Substances SIG: Oral Session
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9780470515945
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_13.x
DO  - doi:10.1111/j.1440-1843.2011.01936_13.x
SP  - 24
EP  - 24
PY  - 2011
ER  - 

TY  - JOUR
TI  - Asthma & Allergy SIG: Oral Session 2
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9780470515945
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_14.x
DO  - doi:10.1111/j.1440-1843.2011.01936_14.x
SP  - 24
EP  - 26
PY  - 2011
ER  - 

TY  - JOUR
TI  - Oeld/Population Health SIG: Oral Session
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9780470515945
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_17.x
DO  - doi:10.1111/j.1440-1843.2011.01936_17.x
SP  - 28
EP  - 30
PY  - 2011
ER  - 

TY  - JOUR
TI  - Pulmonary Physiology & Sleep SIG: Oral Session
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9780470515945
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_18.x
DO  - doi:10.1111/j.1440-1843.2011.01936_18.x
SP  - 30
EP  - 31
PY  - 2011
ER  - 

TY  - JOUR
TI  - Respiratory Nurses SIG: Oral Session 2
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9780470515945
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_2.x
DO  - doi:10.1111/j.1440-1843.2011.01936_2.x
SP  - 9
EP  - 10
PY  - 2011
ER  - 

TY  - JOUR
TI  - Cell Biology/Immunology SIG: Oral Session 2
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9780470515945
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_7.x
DO  - doi:10.1111/j.1440-1843.2011.01936_7.x
SP  - 15
EP  - 16
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstract Presentations from the AABB Annual Meeting San Antonio, TX, October 19–22, 2019
JO  - Transfusion
JA  - Transfusion
VL  - 59
IS  - S3
SN  - 9780470515945
UR  - https://doi.org/10.1111/trf.15462
DO  - doi:10.1111/trf.15462
SP  - 8A
EP  - 220A
PY  - 2019
ER  - 

TY  - JOUR
TI  - Paediatric SIG/Asthma & Allergy SIG: Joint Oral Session
JO  - Respirology
VL  - 16
IS  - s1
SN  - 9780470515945
UR  - https://doi.org/10.1111/j.1440-1843.2011.01936_11.x
DO  - doi:10.1111/j.1440-1843.2011.01936_11.x
SP  - 21
EP  - 22
PY  - 2011
ER  - 
